The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties. The Foundation exists to give all of them a reason to smile, with the ultimate goal of finding a cure.
The mission of the Prevent Cancer Foundation® is saving lives across all populations through cancer prevention and early detection.
Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas.
Catalyst Awards will reward bold, new, potentially transformative ideas to improve the physical, mental, or social well-being and health of people as they age, in a measurable and equitable way. The NAM seeks innovative approaches that aim to extend the human healthspan, especially approaches that challenge existing paradigms or propose new methodologies or concepts. High-risk ideas that could potentially yield high rewards and, in turn, dramatically change the field of healthy longevity are encouraged.
In the spirit of growing scientific collaboration, ALSF has launched the Crazy 8 Initiative to detail roadmaps toward cures for specific, hard-to-treat childhood cancers. In addition to its current grant opportunities, the Crazy 8 Initiative creates a new funding pillar for ALSF, allowing the Foundation to tackle explicit challenges in pediatric cancer research that require substantial support for collaborative teams. ALSF has committed $25 million to support the Crazy 8 Initiative.
Robert Wood Johnson Foundation—Systems for Action: Systems and Services Research to Build a Culture of Health
Systems for Action (S4A) is a signature research program of the Robert Wood Johnson Foundation (RWJF) that builds a Culture of Health by rigorously testing new ways of connecting the nation’s fragmented medical, social, and public health systems.
Grants awarded through this RFA are intended to produce foundational knowledge about the neurobehavioral differences associated with ASD, which will directly inform the development or refinement of tools needed for translational efforts, such as biomarkers and outcome measures. Special emphasis is placed on objective, quantitative measures that may be used in conjunction with standardized clinical measures and genomic information to better triangulate phenotypic and neurobiological variability within and across individuals with ASD.
Grants awarded through this RFA are intended to provide early support for exploratory ideas, particularly those with novel hypotheses for autism. Appropriate projects for this mechanism include those considered higher risk with less assurance of ultimate impact, but with the potential for transformative results.
Cures Within Reach—Preclinical Repurposing Research to Address Meniere's Disease and Related Symptoms / Consequences
This Request for Proposals is seeking preclinical repurposing research projects to address Meniere’s disease (MD) and symptoms/consequences of MD, including tinnitus and hearing loss.
Cures Within Reach—Repurposing Research to Improve Clinical Patient Outcomes in Meniere's Disease and Related Symptoms / Consequences
This Request for Proposals is seeking clinical repurposing trials to address Meniere’s disease (MD) and symptoms/consequences of MD, including tinnitus and hearing loss.
The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2021 Research Fellow Award Program, an initiative supporting researchers at the post-doctorate, medical fellow or junior faculty levels working under the supervision or guidance of a research mentor in the multiple myeloma field. The goal of this initiative is to engage and support young investigators entering the field of multiple myeloma while advancing the understanding of myeloma disease biology and disease risk, treatment and response and drug resistance.
The purpose of this funding opportunity is to provide assistance in the form of grants for the development of innovative clinical quality measures that promote excellence in diagnosis of three categories of disease – acute vascular events, infections and cancer. The initiative aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes and save lives. The initiative’s first area of focus is to develop and validate new measures for diagnostic performance.
Brain Research Foundation’s Scientific Innovations Award (SIA) Program provides funding for innovative science in both basic and clinical neuroscience. This funding mechanism is designed to support creative, exploratory, cutting edge research in well-established research laboratories, under the direction of established investigators.
The Chan Zuckerberg Initiative invites applications for three-year collaborative projects for the generation of healthy, single-cell reference data from ancestrally diverse tissue samples for the Human Cell Atlas (HCA).
The Research Program seeks to benefit humanity by supporting projects in two areas: (1) medical research and (2) science and engineering research.
To encourage a commitment to breast cancer research, the Breast Cancer Alliance (BCA) invites clinical doctors and research scientists, including post docs, whose primary focus is breast cancer research, and who are in the early stages of their career, to apply for funding for the Young Investigator Grant (YIG). This grant is open to applicants at institutions within the United States.
The Margaret Q. Landenberger Research Foundation (“the Foundation”) is a non-profit private foundation which focuses its support on promising early-stage medical researchers. The ideal candidate is affiliated with an outstanding medical research institution and works under the supervision of experienced mentors. The Foundation’s goal is to assist these individuals by funding their current research, with the hope of enabling them to acquire more significant funding. The Foundation does not restrict support to any particular disease or medical condition.
The SCIRTS Portfolio advances novel approaches to improving function and developing curative therapies after SCI. This research is designed to improve understanding and advance the treatment of acute and chronic SCI and includes mechanistic, preclinical, translational and/or clinical studies.
The Michelson Prizes: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery and immunotherapy research for major global diseases.
Bristol Myers Squibb Foundation and National Medical Fellowships—Diversity in Clinical Trials Career Development Program (DCTCDP)
In partnership, the Bristol Myers Squibb Foundation and National Medical Fellowships have created the Diversity in Clinical Trials Career Development Program (DCTCDP) aimed at increasing diversity in clinical trials.